asenapine

Phase 3

Organon & Co. (OGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

8 competitors in Schizophrenia

ITCILumateperone 42 mg

Phase 3

JNJpaliperidone ER Oros

Drug Information

Target Indication

Schizophrenia

Clinical Trial

NCT00212771

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/1/2010

Sycrest

Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

OGN

Organon & Co.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK0663, Etoricoxib / Duration of Treatment : 12 WeeksPhase 3

Recurrent Low Back Pain

MK0217, alendronate sodium / Duration of Treatment : 2 YearsPhase 3

Osteoporosis, Postmenopausal

Tibolone 2.5 mgPhase 3

Postmenopausal Women

Corifollitropin alfaPhase 3

In Vitro Fertilization

A-Phase: tirofiban; Z-Phase simvastatinPhase 3

Acute Coronary Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts